albuterol sulfate metered dose inhaler (PT007) / AstraZeneca - LARVOL DELTA

MITCHELL: A Study Evaluating the Effect of Inhaled PT007(AS MDI) Versus Placebo MDI and Ventolin Evohaler on Lung Function in Adult Participants With Asthma (clinicaltrials.gov) - P2 | N=102 | Recruiting | Sponsor: AstraZeneca | Not yet recruiting ➔ Recruiting

Enrollment open • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases

PT027 Compared to PT007 in Patients With Asthma With Mannitol-induced Acute Airway Obstruction (clinicaltrials.gov) - P3 | N=21 | Completed | Sponsor: AstraZeneca | Recruiting ➔ Completed | N=105 ➔ 21

Enrollment change • Trial completion • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases

MITCHELL: A Study Evaluating the Effect of Inhaled PT007(AS MDI) Versus Placebo MDI and Ventolin Evohaler on Lung Function in Adult Participants With Asthma (clinicaltrials.gov) - P2 | N=102 | Not yet recruiting | Sponsor: AstraZeneca

New P2 trial • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases

PT027 Compared to PT007 in Patients With Asthma With Mannitol-induced Acute Airway Obstruction (clinicaltrials.gov) - P3 | N=105 | Recruiting | Sponsor: AstraZeneca | Trial completion date: Aug 2024 ➔ Dec 2024 | Trial primary completion date: Aug 2024 ➔ Dec 2024

Trial completion date • Trial primary completion date • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases

PUTUO: Phase I PK Study of Budesonide/Albuterol Delivered From PT027 in Healthy Chinese Participants. (clinicaltrials.gov) - P1 | N=14 | Completed | Sponsor: AstraZeneca | Recruiting ➔ Completed

Trial completion

PUTUO: Phase I PK Study of Budesonide/Albuterol Delivered From PT027 in Healthy Chinese Participants. (clinicaltrials.gov) - P1 | N=14 | Recruiting | Sponsor: AstraZeneca | Not yet recruiting ➔ Recruiting

Enrollment open

A Comparison of PT027 vs PT007 Used as Needed in Participants With Asthma (clinicaltrials.gov) - P3 | N=2517 | Completed | Sponsor: Bond Avillion 2 Development LP | Active, not recruiting ➔ Completed | Trial completion date: Mar 2025 ➔ Aug 2024 | Trial primary completion date: Mar 2025 ➔ Aug 2024

Trial completion • Trial completion date • Trial primary completion date • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases

PUTUO: Phase I PK Study of Budesonide/Albuterol Delivered From PT027 in Healthy Chinese Participants. (clinicaltrials.gov) - P1 | N=14 | Not yet recruiting | Sponsor: AstraZeneca

New P1 trial

BAIYUN: A Study to Investigate Efficacy and Safety of PT027 Compared With PT007 in Symptomatic Chinese Adults With Asthma (clinicaltrials.gov) - P3 | N=790 | Recruiting | Sponsor: AstraZeneca | Not yet recruiting ➔ Recruiting

Enrollment open • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases

BAIYUN: A Study to Investigate Efficacy and Safety of PT027 Compared With PT007 in Symptomatic Chinese Adults With Asthma (clinicaltrials.gov) - P3 | N=790 | Not yet recruiting | Sponsor: AstraZeneca

New P3 trial • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases

ACADIA: Evaluating the Efficacy and Safety of PT027 Compared With PT007 Administered As Needed in Participants 12 to < 18 Years of Age With Asthma (clinicaltrials.gov) - P3 | N=440 | Recruiting | Sponsor: AstraZeneca | Not yet recruiting ➔ Recruiting

Enrollment open • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases

PT027 Compared to PT007 in Patients With Asthma With Mannitol-induced Acute Airway Obstruction (clinicaltrials.gov) - P3 | N=105 | Recruiting | Sponsor: AstraZeneca | Trial completion date: Apr 2024 ➔ Nov 2024 | Trial primary completion date: Apr 2024 ➔ Nov 2024

Trial completion date • Trial primary completion date • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases

A Comparison of PT027 vs PT007 Used as Needed in Participants With Asthma (clinicaltrials.gov) - P3 | N=2518 | Active, not recruiting | Sponsor: Bond Avillion 2 Development LP | Recruiting ➔ Active, not recruiting

Enrollment closed • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases

ACADIA: Evaluating the Efficacy and Safety of PT027 Compared With PT007 Administered As Needed in Participants 12 to < 18 Years of Age With Asthma (clinicaltrials.gov) - P3 | N=440 | Not yet recruiting | Sponsor: AstraZeneca

New P3 trial • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases

PT027 Compared to PT007 in Patients With Asthma With Mannitol-induced Acute Airway Obstruction (clinicaltrials.gov) - P3 | N=105 | Recruiting | Sponsor: AstraZeneca | Active, not recruiting ➔ Recruiting

Enrollment open • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases

A Comparison of PT027 vs PT007 Used as Needed in Participants With Asthma (clinicaltrials.gov) - P3 | N=2500 | Recruiting | Sponsor: Bond Avillion 2 Development LP | N=1910 ➔ 2500 | Trial completion date: May 2024 ➔ Mar 2025

Enrollment change • Trial completion date • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases

PT027 Compared to PT007 in Patients With Asthma With Mannitol-induced Acute Airway Obstruction (clinicaltrials.gov) - P3 | N=105 | Active, not recruiting | Sponsor: AstraZeneca | Trial completion date: Jan 2024 ➔ Apr 2024

Trial completion date • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases

PT027 Compared to PT007 in Patients With Asthma With Mannitol-induced Acute Airway Obstruction (clinicaltrials.gov) - P3 | N=105 | Active, not recruiting | Sponsor: AstraZeneca | N=76 ➔ 105 | Trial completion date: Oct 2023 ➔ Jan 2024 | Trial primary completion date: Oct 2023 ➔ Jan 2024

Enrollment change • Trial completion date • Trial primary completion date • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases

PT027 Compared to PT007 in Patients With Asthma With Mannitol-induced Acute Airway Obstruction (clinicaltrials.gov) - P3 | N=76 | Active, not recruiting | Sponsor: AstraZeneca | Trial primary completion date: Dec 2022 ➔ Oct 2023

Trial primary completion date • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases

PT027 Compared to PT007 in Patients With Asthma With Mannitol-induced Acute Airway Obstruction (clinicaltrials.gov) - P3 | N=76 | Active, not recruiting | Sponsor: AstraZeneca | Recruiting ➔ Active, not recruiting | Trial completion date: May 2023 ➔ Oct 2023 | Trial primary completion date: May 2023 ➔ Dec 2022

Enrollment closed • Trial completion date • Trial primary completion date • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases

PT027 Compared to PT007 in Patients With Asthma With Mannitol-induced Acute Airway Obstruction (clinicaltrials.gov) - P3 | N=76 | Recruiting | Sponsor: AstraZeneca | Not yet recruiting ➔ Recruiting

Enrollment open • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases

PT027 Compared to PT007 in Patients With Asthma With Mannitol-induced Acute Airway Obstruction (clinicaltrials.gov) - P3 | N=76 | Not yet recruiting | Sponsor: AstraZeneca

New P3 trial • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases

A Comparison of PT027 vs PT007 Used as Needed in Participants With Asthma (clinicaltrials.gov) - P3 | N=1910 | Recruiting | Sponsor: Bond Avillion 2 Development LP | Not yet recruiting ➔ Recruiting

Enrollment open • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases

A Comparison of PT027 vs PT007 Used as Needed in Participants With Asthma (clinicaltrials.gov) - P3 | N=1910 | Not yet recruiting | Sponsor: Bond Avillion 2 Development LP

New P3 trial • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases

MANDALA: A Study to Assess the Efficacy and Safety of Budesonide/Albuterol Metered-dose Inhaler (BDA MDI/PT027) in Adults and Children 4 Years of Age or Older With Asthma (clinicaltrials.gov) - P3 | N=3123 | Completed | Sponsor: Bond Avillion 2 Development LP | Active, not recruiting ➔ Completed

Trial completion • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases